chondroitin-sulfates has been researched along with Osteosarcoma* in 9 studies
9 other study(ies) available for chondroitin-sulfates and Osteosarcoma
Article | Year |
---|---|
Autograft treated with liquid nitrogen combined with the modified Masquelet technique for bone defect after resection of malignant bone tumors: Two case reports.
Topics: Adult; Autografts; Bone Neoplasms; Carcinoma; Chondroitin Sulfates; Humans; Hydroxyapatites; Liposarcoma; Male; Middle Aged; Nitrogen; Osteosarcoma; Succinates; Tibia; Ulna | 2019 |
Comparative Study of Osteogenic Activity of Multilayers Made of Synthetic and Biogenic Polyelectrolytes.
Polyelectrolyte multilayer (PEM) coatings on biomaterials are applied to tailor adhesion, growth, and function of cells on biomedical implants. Here, biogenic and synthetic polyelectrolytes (PEL) are used for layer-by-layer assembly to study the osteogenic activity of PEM with human osteosarcoma MG-63 cells in a comparative manner. Formation of PEM is achieved with biogenic PEL fibrinogen (FBG) and poly-l-lysine (PLL) as well as biotinylated chondroitin sulfate (BCS) and avidin (AVI), while poly(allylamine hydrochloride) (PAH) and polystyrene sulfonate (PSS) represent a fully synthetic PEM used as a reference system here. Surface plasmon resonance measurements show highest layer mass for FBG/PLL and similar for PSS/PAH and BCS/AVI systems, while water contact angle and zeta potential measurements indicate larger differences for PSS/PAH and FBG/PLL but not for BCS/AVI multilayers. All PEM systems support cell adhesion and growth and promote osteogenic differentiation as well. However, FBG/PLL layers are superior regarding MG-63 cell adhesion during short-term culture, while the BCS/AVI system increases alkaline phosphatase activity in long-term culture. Particularly, a multilayer system based on affinity interaction like BCS/AVI may be useful for controlled presentation of biotinylated growth factors to promote growth and differentiation of cells for biomedical applications. Topics: Avidin; Bone Neoplasms; Cell Line, Tumor; Chondroitin Sulfates; Fibrinogen; Humans; Osteogenesis; Osteosarcoma; Polyamines; Polyelectrolytes; Polylysine | 2017 |
Relationships between serum biomarker levels and clinical presentation of human osteosarcomas.
Currently, serum biomarkers play an important role as sensitive tools for monitoring the cancer development and progression. Each biomarker represents a specific pathogenesis and has different predictive capability. In order to identify their characteristics in human osteosarcoma, multiple potential biomarkers were analyzed simultaneously with clinical presentations.. Blood samples were collected from 28 osteosarcoma patients and 30 healthy matched controls. Specific clinical presentations were recorded, including: tumor volume, estimated based on three-dimensional MRI volumetric measurement; metastasis status; and histological cell types. Serum biomarkers analyzed by ELISA-based assays were bone-specific alkaline phosphatase (BALP), vascular endothelial growth factor (VEGF), hyaluronic acid (HA) and chondroitin sulfate WF6 (WF6). Serum lactate dehydrogenase (LDH) was analyzed by a photometric-based system.. Serum BALP, LDH and WF6 levels of osteosarcoma patients were significantly higher than those of healthy controls, whereas HA and VEGF levels were not significantly different between the two groups. Serum BALP and LDH were positively correlated with tumor volume, (correlation coefficients 0.5 and 0.4, respectively). Serum BALP from metastasis and osteoblastic subtype group had a significantly higher level than that found in non-metastasis and non-osteoblastic subtypes group, respectively. Upon multivariate analysis, tumor volume was the only factor which correlated with BALP levels.. Of the biomarkers analyzed in this study, serum BALP was the most reliable and sensitive for estimating tumor volume. A high level of serum WF6 reflects alteration of the extracellular matrix component of tumors. Both serum biomarkers can be expected to be further explored for use in specific clinical monitoring. Topics: Adolescent; Adult; Alkaline Phosphatase; Biomarkers, Tumor; Bone Neoplasms; Case-Control Studies; Child; Chondroitin Sulfates; Female; Humans; Hyaluronic Acid; L-Lactate Dehydrogenase; Male; Middle Aged; Osteosarcoma; Tumor Burden; Vascular Endothelial Growth Factors; Young Adult | 2011 |
Glycosaminoglycan composition changes with MG-63 osteosarcoma osteogenesis in vitro and induces human mesenchymal stem cell aggregation.
Osteogenic differentiation is coordinated by the exposure of cells to temporal changes in a combination of growth factors and elements within the extracellular matrix (ECM). Many of the key proteins that drive these changes share the property of being dependent on ECM glycosaminoglycans (GAGs) for their activity. Here, we examined whether GAGs isolated from proliferating, differentiating and mineralizing MG-63 osteosarcoma cells differed in their physical properties, and thus in their capacities to coordinate the osteogenic cascade both in human MG-63 osteosarcoma cells and primary human mesenchymal stem cells (hMSCs). Our results show that the size distribution of GAGs, the expression of GAG-carrying proteoglycan cores and the expression of enzymes involved in their modification systematically change as MG-63 cells mature in culture. When dosed back onto cells exogenously in soluble form, GAGs regulated MG-63 survival and growth in a dose-dependent manner, but not differentiation in either cell type. In contrast, hMSCs aggregated into distinct colonies when grown on GAG-coated substrates, while MG-63 cells did not. Heparin-coated substrates improved hMSC viability without inducing aggregation. These results suggest a complex role for GAGs in coordinating the emergence of the osteoblast phenotype, and provide further evidence for the use of heparans in bone tissue repair applications. Topics: Cell Aggregation; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Shape; Cell Survival; Chondroitin Sulfates; Dermatan Sulfate; Fibroblast Growth Factor 2; Glycosaminoglycans; Heparan Sulfate Proteoglycans; Heparin; Humans; Mesenchymal Stem Cells; Osteogenesis; Osteosarcoma; Phenotype; Protein Binding; Time Factors; Transforming Growth Factor beta | 2009 |
Involvement of chondroitin sulfate E in the liver tumor focal formation of murine osteosarcoma cells.
Cell surface heparan sulfate plays a critical role in regulating the metastatic behavior of tumor cells, whereas the role of chondroitin sulfate/dermatan sulfate (CS/DS) has been little understood in this context. Here, we characterized CS/DS chains from the murine osteosarcoma cell line LM8G7, which forms tumor nodules in liver. Structural analysis of the CS/DS chains showed a higher proportion of GlcUA beta 1-3GalNAc(4,6-O-disulfate) (E-units) in LM8G7 (12%) than in its parental cell line LM8 (6%), which rarely forms tumors in the liver. Immunostaining with GD3G7, an antibody specific to E-units, confirmed the higher expression of the epitope in LM8G7 than LM8 cells. The tumor focal formation of LM8G7 cells in the liver in mice was effectively inhibited by the preadministration of CS-E (rich in E-unit) or the preincubation of the antibody GD3G7 with the tumor cells. CS-E or GD3G7 inhibited the adhesion of LM8G7 cells to a laminin-coated plate in vitro. In addition, the invasive ability of LM8G7 cells in vitro was also reduced by the addition of CS-E or the antibody. Further, CS-E or the antibody inhibited the proliferation of LM8G7 cells dose dependently. The binding of LM8G7 cells to VEGF in vitro was also significantly reduced by CS-E and GD3G7. Thus, the present study reveals the significance of highly sulfated CS/DS structures in the liver colonization of osteosarcoma cells and also provides a framework for the development of GAG-based anticancer molecules. Topics: Animals; Antibodies, Neoplasm; Cell Adhesion; Chondroitin Sulfates; Cytokines; Female; Fibroblast Growth Factor 2; Hepatocyte Growth Factor; Humans; Liver Neoplasms; Mice; Mice, Inbred C3H; Midkine; Osteosarcoma; Time Factors; Vascular Endothelial Growth Factor A | 2009 |
A novel use of TAT-EGFP to validate techniques to alter osteosarcoma cell surface glycosaminoglycan expression.
Several methods to alter cell surface glycosaminoglycan (GAG) expression have previously been described, including treatments with chlorate to reduce the addition of charged sulfate groups, xyloside compounds to displace GAGs from their core proteins, and GAG lyases, such as heparinase and chondroitinase, to release GAG fragments from the cell layer. While these methods are useful in identifying cellular mechanisms which are dependent on GAGs, they must be stringently validated to assess results in the appropriate context. To determine the most useful technique for the evaluation of GAG function in osteogenesis, MG-63 osteosarcoma cells were systematically treated with these agents and evaluated for changes in cell surface GAGs using a TAT-EGFP fusion protein. TAT, a protein transduction domain from the HIV-1 virus, requires cell surface GAGs to traverse cell membranes. The EGFP component provides a method to assess protein entry into cells in both qualitative and quantitative tests. Here, TAT-EGFP transduction analysis confirmed radiochemical and physiological data that chlorate effectively disrupts GAG expression. TAT-EGFP entry into cells was also inhibited by the exogenous application of commercial heparin and GAGs extracted from MG-63 cells as well as by the pre-treatment of cells with chondroitinase ABC. However, neither heparinase III treatment nor the addition of exogenous chondroitin-6-sulfate affected TAT-EGFP entry into cells. In addition, xyloside-beta-D-naphthol and xyloside-beta-D-cis/trans-decahydro-2-naphthol treatment could not induce significant phenotypic change in these cells, and the unaffected TAT-EGFP transduction confirmed that this was due to an inability to efficiently prime GAG synthesis. The use of TAT-EGFP is thus a useful technique to specifically evaluate cell surface GAG expression in a simple, quantifiable manner, and avoids the complications involved with conventional radiochemical assays or analytical chromatography. Topics: Biological Transport; Cell Line, Tumor; Cell Membrane; Chondroitin Lyases; Chondroitin Sulfates; Flow Cytometry; Glycosaminoglycans; Glycosides; Green Fluorescent Proteins; Heparin; Heparin Lyase; Humans; Microscopy, Confocal; Osteosarcoma; Recombinant Fusion Proteins; tat Gene Products, Human Immunodeficiency Virus | 2007 |
Hyaline cartilage: in vivo and in vitro assessment with magnetization transfer imaging.
To elucidate the magnetization transfer (MT) effects of major components of hyaline cartilage.. The authors evaluated the MT effect of type II collagen and chondroitin sulfate phantoms (concentrations of 0.6%, 1.2%, 2.4%, 4.8%, 9.6%, and 19.2%), mass-cultured rat osteosarcoma-derived cells, and normal articular cartilage of the knee.. The MT effect of collagen yielded a decrease in signal intensity of 10% (1.2% collagen) to 31% (19.2% collagen); the decrease varied linearly with collagen concentration. Chondroitin sulfate did not have a statistically significant MT effect. Cell pellets showed a decrease in signal intensity of 22%-26%, which was greater than that of 4.8% collagen. Normal articular cartilage of the knees showed a decrease in signal intensity of 38%-48%.. The major role of collagen in MT contrast of hyaline cartilage was confirmed. In addition, a higher cellular contribution to the MT effect was also demonstrated. Topics: Adolescent; Adult; Animals; Cartilage, Articular; Cattle; Child; Chondroitin Sulfates; Collagen; Female; Humans; In Vitro Techniques; Knee Joint; Magnetic Resonance Imaging; Male; Middle Aged; Osteosarcoma; Phantoms, Imaging; Rats; Swine; Tumor Cells, Cultured | 1996 |
Proteoglycan form of colony-stimulating factor-1 (proteoglycan-100). Stimulation of activity by glycosaminoglycan removal and proteolytic processing.
A proteoglycan had been isolated from the conditioned media of a human osteosarcoma cell line and had tentatively been named proteoglycan-100 (PG-100) because of the size of its core glycoprotein. Amino acid sequencing of the purified proteoglycan and cDNA analysis were consistent with the assumption that PG-100 is identical with the proteoglycan form of CSF-1 (or macrophage colony-stimulating factor). PG-100 induced mouse macrophage differentiation. Proliferation of macrophages was stimulated in a dose-dependent manner. On a molar basis, however, about 100- to 300-fold higher doses of PG-100 than of recombinant human (rh)CSF-1 were required for the half-maximal growth-stimulating effect. Upon enzymatic removal of the glycosaminoglycan chain, the purified core protein exhibited higher activity, but was still about 20-fold less active than rhCSF-1. Incubation of the purified proteoglycan for 48 h at 37 degrees C led to the formation of a glycosaminoglycan-free 50-kDa fragment either by autoproteolysis or by the action of a protease not yet identified. The purified fragment exhibited almost the same biologic activity as rhCSF-1. The glycosaminoglycan chain of the growth factor was not only shown to inhibit CSF-1 activity but also to increase the stability of the core protein when the CSF-1-producing osteosarcoma cells were maintained in a collagen lattice. These findings provide a link between a soluble, highly active cytokine and its extracellular matrix storage form of comparatively low activity. Topics: Amino Acid Sequence; Base Sequence; Biglycan; Blotting, Northern; Chondroitin Sulfates; Decorin; Endopeptidases; Extracellular Matrix Proteins; Humans; Macrophage Activation; Macrophage Colony-Stimulating Factor; Molecular Sequence Data; Osteosarcoma; Proteoglycans; Recombinant Proteins; Tumor Cells, Cultured | 1995 |
Newly synthesized glycoconjugates from two cell lines derived from rat osteogenic sarcoma: effects of Matrigenin activity from bone.
An activity isolated from bovine bone was previously shown to stimulate proteoglycan synthesis by several connective tissue cell lines from normal tissues (Matrigenin activity). The effect of this activity on glycoconjugate synthesis by two osteoblastic cell lines, ROS 17/2 and UMR-106, derived from rat osteogenic sarcoma, was examined after labelling of the cells with [3H]glucosamine and [35S]sulfate. The glycoconjugates from the cell layers and the media were separated by DEAE-Sephacel chromatography and the anionic glycoconjugates of the media were further analyzed by chromatography on Sepharose CL-2B and enzymatic digestion of the papain-released glycosaminoglycans. The ROS 17/2 cells secreted at least two distinct species of proteoglycan (one heparan sulfate rich and the other chondroitin sulfate rich), whereas the UMR-106 secreted primarily an anionic glycoprotein. The addition of Matrigenin activity to the ROS 17/2 cells resulted in stimulation of incorporation of radioactivity into the proteoglycan and hyaluronic acid, but in UMR-106 cultures it resulted in decreased incorporation into the anionic glycoprotein. The decrease in incorporation into the anionic glycoprotein from the medium was shown, by alkaline beta-elimination, to have occurred mainly in the oligosaccharide fraction, relative to control cultures. Topics: Animals; Bone and Bones; Chondroitin Sulfates; Chromatography; Glucosamine; Glycoconjugates; Glycoproteins; Glycosaminoglycans; Heparitin Sulfate; Osteoblasts; Osteosarcoma; Papain; Rats; Sulfates; Sulfur Radioisotopes; Tissue Extracts; Tritium; Tumor Cells, Cultured | 1991 |